ReviewStem cell reviews and reports2025
Spinal Cord Injury 2.0: Bridging the Gap Between Neurobiology, Technology, and Hope in the Era of Precision Medicine.
Review in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Emerging Regenerative Medicine for Spinal Cord Injury: Spinal Cord Organoids-on-a-Chip.International journal of molecular sciences · 2026Review
- Arachidonic acid metabolism in spinal cord injury.Journal of advanced research · 2026Review
- circ_0044235 exacerbates neuroinflammation and apoptosis following spinal cord injury by targeting miR-338-5p.Journal of orthopaedic surgery and research · 2026Article
- Towards an understanding of disturbed sleep phenotypes after traumatic spinal cord injury.Journal of rehabilitation medicine · 2026Observational
- The Spinal Cord Injury Paradigm and the Translational Reality Check: Navigating the Perils of Combinatorial Therapies and Precision Illusions.Stem cell reviews and reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a devastating neurological condition with profound motor, sensory, and autonomic consequences, affecting 10-83 individuals per million annually worldwide. This review explores the evolving SCI landscape, from acute ionic imbalance, excitotoxicity, and vascular disruption to chronic neuroinflammation and glial fibrosis, which collectively impede neural regeneration. Breakthroughs in regenerative bioengineering-such as stem cell-driven neurogenesis and CRISPR-Cas9-mediated axonal growth modulation-are converging with neurotechnological advances, including spinal neuromodulation, brain-computer interface integration, and AI-enhanced robotic locomotor systems, to redefine therapeutic frontiers. Precision medicine, guided by multi-omic biomarker stratification and patient-specific computational modeling, enables individualized intervention strategies. Despite unprecedented progress, translation to the clinic demands optimized preclinical models, harmonized trial methodologies, and ethical frameworks ensuring equitable access. Together, these innovations herald a shift from compensatory care toward structural repair and functional restoration in SCI.
Indexed as
Identifiers
40956372What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.